WO2003106382A3 - Reversed liquid crystalline phases with non-paraffin hydrophobes - Google Patents

Reversed liquid crystalline phases with non-paraffin hydrophobes Download PDF

Info

Publication number
WO2003106382A3
WO2003106382A3 PCT/US2003/018457 US0318457W WO03106382A3 WO 2003106382 A3 WO2003106382 A3 WO 2003106382A3 US 0318457 W US0318457 W US 0318457W WO 03106382 A3 WO03106382 A3 WO 03106382A3
Authority
WO
WIPO (PCT)
Prior art keywords
absorption
surfactant
compositions
hydrophobes
paraffin
Prior art date
Application number
PCT/US2003/018457
Other languages
French (fr)
Other versions
WO2003106382A2 (en
Inventor
David M Anderson
Original Assignee
Lyotropic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyotropic Therapeutics Inc filed Critical Lyotropic Therapeutics Inc
Priority to AU2003243509A priority Critical patent/AU2003243509B2/en
Priority to CA002488701A priority patent/CA2488701A1/en
Priority to EP03760279A priority patent/EP1539099A4/en
Priority to JP2004513218A priority patent/JP2005532366A/en
Publication of WO2003106382A2 publication Critical patent/WO2003106382A2/en
Publication of WO2003106382A3 publication Critical patent/WO2003106382A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases

Abstract

Compounds which are otherwise difficult to solubilize, such as, for example, pharmaceutical actives difficult for the body to absorb, are solubilized into a composition using a solvent system that is a structured fluid. The structured fluid is a reversed cubic phase or reversed hexagonal phase material, or a combination thereof, which includes a polar solvent, a surfactant and a non-paraffinic liquid with a high octanol-water partition coefficient which does not qualify as a surfactant. The compositions thus formed are able to enhance absorption of drugs by the induction of local, transient nanopores in biomembrane absorption barriers and particularly those in which efflux mechanisms, such as those associated with P-glycoprotein and/or cytochrome 3A4, are active. The compositions and methods that are used for solubilizing pharmaceutical actives in structured fluids can simultaneously accomplish solubilization of difficultly soluble drugs and enhancement of absorption.
PCT/US2003/018457 2002-06-13 2003-06-13 Reversed liquid crystalline phases with non-paraffin hydrophobes WO2003106382A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003243509A AU2003243509B2 (en) 2002-06-13 2003-06-13 Reversed liquid crystalline phases with non-paraffin hydrophobes
CA002488701A CA2488701A1 (en) 2002-06-13 2003-06-13 Reversed liquid crystalline phases with non-paraffin hydrophobes
EP03760279A EP1539099A4 (en) 2002-06-13 2003-06-13 Reversed liquid crystalline phases with non-paraffin hydrophobes
JP2004513218A JP2005532366A (en) 2002-06-13 2003-06-13 Reverse liquid crystal phase with non-paraffinic hydrophobic material

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38790902P 2002-06-13 2002-06-13
US60/387,909 2002-06-13

Publications (2)

Publication Number Publication Date
WO2003106382A2 WO2003106382A2 (en) 2003-12-24
WO2003106382A3 true WO2003106382A3 (en) 2004-07-22

Family

ID=29736379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018457 WO2003106382A2 (en) 2002-06-13 2003-06-13 Reversed liquid crystalline phases with non-paraffin hydrophobes

Country Status (5)

Country Link
EP (1) EP1539099A4 (en)
JP (1) JP2005532366A (en)
AU (1) AU2003243509B2 (en)
CA (1) CA2488701A1 (en)
WO (1) WO2003106382A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968049A1 (en) * 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CN108548931A (en) * 2018-05-09 2018-09-18 南京岚煜生物科技有限公司 Free thyroxine fT4 kits and preparation and detection method are detected based on micro-fluidic chip

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008537A1 (en) * 1989-02-06 1990-08-09 Abbott Laboratories Pharmaceutical compositions for oral administration
WO1998047487A1 (en) * 1997-04-17 1998-10-29 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6071524A (en) * 1994-11-10 2000-06-06 L'oreal Oily phase in aqueous phase dispersion stabilized by cubic gel particles and method of making
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747252B2 (en) * 1997-09-09 2002-05-09 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
WO2002043696A1 (en) * 2000-11-29 2002-06-06 Lyotropic Therapeutics, Inc. Solvent systems for pharmaceutical agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008537A1 (en) * 1989-02-06 1990-08-09 Abbott Laboratories Pharmaceutical compositions for oral administration
US6071524A (en) * 1994-11-10 2000-06-06 L'oreal Oily phase in aqueous phase dispersion stabilized by cubic gel particles and method of making
WO1998047487A1 (en) * 1997-04-17 1998-10-29 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1539099A4 *

Also Published As

Publication number Publication date
JP2005532366A (en) 2005-10-27
EP1539099A2 (en) 2005-06-15
AU2003243509A1 (en) 2003-12-31
CA2488701A1 (en) 2003-12-24
AU2003243509B2 (en) 2009-08-20
WO2003106382A2 (en) 2003-12-24
EP1539099A4 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
PE20081477A1 (en) LYOPHILIZED FORMULATION MAB ABETA
ECSP088524A (en) BETA 4 AMILOID ANTIBODIES WITH GLYCOSILATION IN THE VARIABLE REGION
AR049009A1 (en) GEL - CREAM CONTAINING IVERMECTINE
ATE538797T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NEUROACTIVE STEROID AND USES THEREOF
EA200601588A1 (en) STABILIZED SUBSTITUTED SOLID SOLUTIONS OF LIPOFILE MEDICINES
CL2008001813A1 (en) COMPOUNDS DERIVED FROM QUINOLIN-3-CARBONITRILE SUBSTITUTED WITH PIPERAZINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS ARTHRITIS, INFLAMMATION, CANCER BETWEEN OTHERS (DIV. SOL. 266-04).
EP2269631A3 (en) Pharmaceutical compositions comprising botulinum neurotoxin for use in medicine and cosmetics
HRP20050676B1 (en) Liquid pharmaceutical formulations of palonosetron
CA2466549A1 (en) Colloidal and colloidal-like systems in aqueous, clay-based fluids
AR053737A1 (en) PEDIATRIC FORMULATION OF TOPIRAMATO
BR0111206A (en) Arylmethylamine derivatives for use as tryptase inhibitors
ATE270544T1 (en) SEMI-SOLID MEDICINAL PREPARATION CONTAINING ISOTRETINOIN
PE20071003A1 (en) FEXOFENADINE SUSPENSION FORMULATION
AR033466A1 (en) STABILIZED PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
JP2008523153A5 (en)
ATE275393T1 (en) SOLID DISPERSIONS WITH NITRATACTIVE ACTIVE INGREDIENTS
AR048878A1 (en) TOPIC COMPOSITIONS OF METADONA AND METHODS FOR USE
RS52651B (en) Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6s)-tetrahydrofolates
BRPI0411306A (en) pharmaceutical compositions comprising vitamin D active compounds
AR059844A1 (en) NEW TOPICAL COMPOSITIONS IN THE FORM OF EMULSION AC / AG THAT INCLUDE A PROPENETRANT GLYCOL
EA200300047A1 (en) TRANSPARENT WATER ANESTHETIC TOOL
CL2004001012A1 (en) COMPOUNDS DERIVED FROM MACROLIDS OF 14 OR 15 MEMBERS, REPLACED IN POSITION 4 "; PROCEDURE FOR PREPARATION; PHARMACEUTICAL COMPOSITION THAT INCLUDES IT; AND ITS USE FOR THE TREATMENT OR PROFILAXIS OF SYSTEMIC MICROBIAL OR TOPICAL INFECTIONS
SE0000774D0 (en) New formulation
PT1094791E (en) TIXOTROPIC FORMULATIONS FOR FILLING HARD CAPSULES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2488701

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003243509

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004513218

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003760279

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003760279

Country of ref document: EP